Ascend specializes in the manufacturing of adeno-associated virus (AAV) gene therapies, providing tailored support throughout the pre-clinical and clinical development stages. The company addresses the need for scalable and efficient production processes, enabling partners to deliver life-changing therapies to patients more quickly and affordably.

Autobahn Therapeutics is developing orally administered small molecule prodrugs using a brain-targeting chemistry platform to create tailored therapies for neuropsychiatric and neuroimmunologic disorders. Their approach focuses on restoring brain health by leveraging validated human biology and biomarker-driven development to address the progressive nature of these debilitating conditions.

AviadoBio develops gene therapies utilizing a neuroanatomy-led approach to deliver treatments directly to the central nervous system for patients with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company addresses the lack of effective therapies for these neurodegenerative disorders by maximizing therapeutic potential to potentially halt or reverse disease progression.

Maxion Therapeutics utilizes its patented KnotBody® technology to develop engineered antibody therapeutics targeting ion channel and GPCR-driven diseases, which are often inadequately treated by existing small molecule drugs. The company focuses on creating safe, effective, and long-acting treatments for chronic pain, autoimmune disorders, and cardiovascular diseases, addressing a significant unmet medical need for over 1.8 billion patients worldwide.

Nocion Therapeutics develops nocions, small molecules that selectively target inflamed nociceptors through large-pore channels to inhibit sodium channels, providing sustained relief from conditions such as chronic cough, pain, and itch. This targeted approach minimizes off-target effects and enhances potency compared to traditional sodium channel blockers, addressing significant unmet medical needs in neurogenic inflammation.

ODAIA provides an AI‑driven platform that unifies pharmaceutical commercial data and delivers predictive analytics to identify high‑potential healthcare professionals. Its dynamic, explainable machine‑learning models generate real‑time HCP segmentation and forecast prescription trends, giving sales reps prioritized call lists and managers actionable dashboards for coaching and strategy adjustments.

Ollin Bio develops novel bispecific antibody therapies for severe ophthalmic diseases like wet AMD and DME. Their lead candidate, OLN324, targets VEGF-A and Angiopoietin-2 to improve anatomic outcomes beyond current anti-VEGF treatments.

The company develops T cell engager antibodies that selectively deplete pathogenic immune cells, aiming to induce long-term remission in patients with chronic immune-mediated diseases. This therapeutic platform seeks to eliminate the need for continuous immunosuppression by resetting the immune system.

RegASK utilizes artificial intelligence to provide curated regulatory intelligence and risk assessments, enabling organizations to navigate complex compliance landscapes efficiently. The platform offers tailored insights and expert guidance, helping businesses proactively manage regulatory changes and mitigate compliance risks.

Sudo Bio provides a cloud‑based platform that automates the integration, cleaning, normalization, and statistical analysis of multi‑omics datasets, allowing researchers and clinicians to extract actionable insights without deep bioinformatics expertise.